SPARC II期试验两年结果:前列腺癌立体定向放疗同步病灶聚焦推量
SPARC II期试验评估CyberKnife立体定向体部放疗同步整合推量治疗不利中危至高危局限前列腺癌的两年晚期毒性和生活质量。20例患者接受36.25 Gy/5次、病灶推量≤47.5 Gy并联合雄激素剥夺治疗,中位随访54个月。2年RTOG≥2级泌尿和胃肠毒性累积发生率分别为35%和5%,无晚期3级毒性,生活质量无临床显著恶化,但性功能评分下降。
要点
- 2年≥2级泌尿毒性累积发生率35%,胃肠毒性5%,无晚期3级毒性。
- 2年时2级泌尿和胃肠毒性患病率均为0%,生活质量及泌尿症状无临床显著恶化。
- 性功能评分较基线下降,中位IIEF-5从18降至10。
核心结论
- CyberKnife-based SBRT delivering 36.25 Gy to the prostate with a simultaneous integrated boost ≤47.5 Gy is well tolerated at 2 years.
研究设计与样本
- SPARC II期试验纳入新诊断、活检证实的不利中危至高危局限前列腺癌患者,要求至少满足Gleason≥4+3、MRI定义T3a N0或PSA≥20之一,且MRI定义DIL≤2个。
- 参与者接受CyberKnife 36.25 Gy/5次同步病灶推量≤47.5 Gy,并全部接受雄激素剥夺治疗。
- 2013年至2023年共入组20例,中位随访54个月(IQR 24-108个月)。
主要发现
- 2年RTOG≥2级泌尿毒性累积发生率为35%(95%CI 15%-59%),胃肠毒性为5%(95%CI 1%-25%)。
- 2年时2级泌尿和胃肠毒性患病率均为0%,无晚期3级泌尿和胃肠毒性。
- 2年EQ5D-5L生活质量、IPSS评分和泌尿生活质量评分较基线无临床显著恶化。
- 2年IIEF-5性功能评分中位10(IQR 5-18),较基线中位18(IQR 6-22)下降。
- 迄今报告1例生化复发。
关键数值与推荐
- DIL的D95中位剂量为47.43 Gy。
- 2年RTOG≥2级泌尿毒性累积发生率35%(95%CI 15%-59%),胃肠毒性5%(95%CI 1%-25%)。
临床怎么用
- 对于不利中危至高危局限前列腺癌,CyberKnife SBRT 36.25 Gy/5次同步DIL推量≤47.5 Gy联合ADT的两年毒性可接受。
- 治疗前应告知患者泌尿毒性累积风险及性功能下降可能。
局限性
- 样本量小(20例),随访时间有限。
- 单臂设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) with focal boost to the dominant intraprostatic lesion (DIL) provides a strategy to enhance outcomes in high-risk localized prostate cancer while minimizing toxicity. This study assessed late toxicity and quality of life (QOL) following CyberKnife-based SBRT with a simultaneous integrated boost in localized prostate cancer. METHODS AND MATERIALS: Patients with newly diagnosed, biopsy-proven unfavorable intermediate- to high-risk localized prostate cancer (at least one of the following: Gleason ≥ 4+3, MRI-defined T3a N0, PSA ≥ 20) with ≤2 MRI-defined DILs were enrolled. Participants received 36.25 Gy in 5 fractions with a simultaneous focal boost ≤47.5 Gy delivered using CyberKnife. All participants received androgen deprivation therapy. The current analysis reports RTOG-assessed late genitourinary (GU) and gastrointestinal (GI) toxicity, late International Prostate Symptom Score and urinary QOL, late International Index of Erectile Function 5-Questionnaire assessed sexual function, late EQ5D-5L QOL, and biochemical outcomes at 2 years. RESULTS: Between 2013 and 2023, 20 participants were enrolled with a median follow-up of 54 months (IQR, 24-108 months). The median D95 dose delivered to the DIL was 47.43 Gy. At 2 years, the cumulative rate of RTOG-assessed grade ≥2 GU and GI toxicity was 35% (95% CI, 15%-59%) and 5% (95% CI, 1%-25%), respectively. The prevalence of grade 2 GU and GI toxicity at 2 years was 0% and there was no late grade 3 GU and GI toxicity. There was no clinically significant worsening of EQ5D-5L-assessed QOL, International Prostate Symptom Score score, and urinary QOL scores at 2 years compared with baseline. There was a reduction in International Index of Erectile Function 5-Questionnaire scores for sexual function at 2 years (median 10; IQR, 5-18) from baseline (median 18; IQR, 6-22). There is one case of biochemical relapse reported to date. CONCLUSIONS: CyberKnife-based SBRT delivering 36.25 Gy to the prostate with a simultaneous integrated boost ≤47.5 Gy is well tolerated at 2 years. The cumulative rates of grade ≥2 GU and GI toxicity were 35% and 5%, respectively, consistent with other contemporary SBRT trials with and without focal boost.
引用
- Yasar B, Suh YE, Chapman E, et al. Two-Year Outcomes of the SPARC Phase II Trial: Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 41529792. doi:10.1016/j.ijrobp.2025.12.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。